
A Focus on Bipolar Depression
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Meeting Slides

Clinical Tools
Mood Disorder Questionnaire
A commonly used, sensitive, and specific screening questionnaire for bipolar disorder. A score of 7 or more across three criteria suggests the presence of bipolar disorder (Hirschfeld RM, et al. Am J Psychiatry. 2000;157(1):1873-1875).
Quick Inventory of Depressive Symptomatology—Self Report
A 16-item self-report assessment of 9 DSM-IV symptom criteria for major depressive disorder. Patients rate items as not present, mild, moderate, or severe with scores ranging from 0 to 27 (0-5, no depression; 6-10, mild depression; 11-15, moderate depression; 16-20, severe depression; >20, very severe depression) (Berk M, et al. Bipolar Disord. 2007;9(6):571-579).
Guidelines
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: 2013 update.
Yatham LN, et al. Bipolar Disord. 2013;15(1):1-44.
VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults
Department of Veterans Affairs, Department of Defense. Clinical Practice Guideline for Management of Bipolar Disorder in Adults. Washington, DC: Department of Veterans Affairs, Department of Defense; 2010.
Diagnostic and Statistical Manual of Mental Disorders (Fifth edition)
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fifth edition). Arlington, VA: American Psychiatric Publishing; 2013.
Other Resources
Depression and Bipolar Support Alliance
The Depression and Bipolar Support Alliance (DBSA) offers resources for patients, materials for clinicians, information on mental health research as well as listings to patient support groups across the United States.
Suggested Readings
Clinical differences between bipolar and unipolar depression
Forty L, et al. Br J Psychiatry. 2008;19(5):388-389.
Strategies for monitoring outcomes in patients with bipolar disorder
Ketter TA. Prim Care Companion J Clin Psychiatry. 2010;12(suppl 1):10-16.
Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study
Loebel A, et al. Am J Psychiatry. 2014;171(2):160-168.
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study
Loebel A, et al. Am J Psychiatry. 2014;171(2):169-177.
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders
McIntyre RS, et al. Ann Clin Psychiatry. 2012;24(1):69-81.
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid medical conditions: Diagnostic, assessment, and treatment principles
Ramasubbu R, et al. Ann Clin Psychiatry. 2012;24(1):82-90.
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions
Ramasubbu R, et al. Ann Clin Psychiatry. 2012;24(1):91-109.
The neurobiology of the switch process in bipolar disorder: a review
Salvadore G, et al. J Clin Psychiatry 2010;71:1488-1501.
The functional neuroanatomy of bipolar disorder: a consensus model
Strakowski SM, et al. Bipolar Disord. 2012;14(4):313-325.
Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)
Thase ME, et al. J Clin Psychopharmacol. 2006;26(6):600-609.
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
Tohen M, et al. Arch Gen Psychiatry. 2003;60(11):1079-1088.
Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression.
McElroy SL, Keck PE. J Clin Psychiatry. 2014;75(1):46-61.

Scientific Insights Into Bipolar Disorder
Michael E. Thase, MD
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Improved Diagnostic and Management Strategies
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Overcoming Diagnostic Challenges, Targeting Remission, and Optimizing Cardiometabolic Health
Translating Research Into Practice
Translating Reseach Into Practice
New Approaches to Optimizing Patient Outcomes
Accelerating Diagnosis, Achieving Remission, and Encouraging Adherence
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Managing Patients Across the Disease Spectrum
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices for Emergency Care
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Consensus and Controversies Across the Spectrum of Patient Presentations
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Finding the Way Forward
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
Best Practices for Screening, Diagnosis, and Management